Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 26
- −3 vs. Q3 2024
- Portfolio value
- $212.2M
- −$119.2M (−36.0%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IONSIonis Pharmaceuticals Inc | COM | 505,007 | $17.7M | 8.3% | +250,007+98.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 360,000 | $16.9M | 8.0% | +44,000+13.9% | Added | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,787,003 | $15.1M | 7.1% | +487,500+37.5% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 750,000 | $14.4M | 6.8% | 00.0% | Unchanged | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,055,000 | $13.9M | 6.5% | −855,121−44.8% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,648,523 | $12.1M | 5.7% | −480,250−22.6% | Reduced | History |
| DVAXDynavax Technologies Corp | COM NEW | 860,000 | $11.0M | 5.2% | −466,234−35.2% | Reduced | History |
| NGNENeurogene Inc. | COM | 442,761 | $10.1M | 4.8% | −561,530−55.9% | Reduced | History |
| EOLSEvolus, Inc. | COM | 895,524 | $9.89M | 4.7% | −274,476−23.5% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 245,272 | $9.61M | 4.5% | +245,272 | New | History |
| UNCYUnicycive Therapeutics, Inc. | COM | 10,980,000 | $8.72M | 4.1% | +2,421,000+28.3% | Added | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,170,194 | $7.93M | 3.7% | −93,478−2.9% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 3,009,392 | $7.07M | 3.3% | +197,437+7.0% | Added | History |
| JSPRJasper Therapeutics, Inc. | COM NEW | 322,380 | $6.89M | 3.2% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 158,092 | $6.65M | 3.1% | −91,908−36.8% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 275,000 | $6.00M | 2.8% | 00.0% | Unchanged | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.25M | 2.5% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 300,000 | $4.93M | 2.3% | +300,000 | New | History |
| CNTXContext Therapeutics Inc. | COM | 4,683,711 | $4.92M | 2.3% | −2,251,271−32.5% | Reduced | History |
| VYGRVoyager Therapeutics, Inc. | COM | 826,751 | $4.69M | 2.2% | −133,202−13.9% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 228,803 | $4.44M | 2.1% | −285,856−55.5% | Reduced | History |
| MREOMereo BioPharma Group plc | SPON ADS | 1,150,000 | $4.03M | 1.9% | +1,150,000 | New | History |
| RZLTRezolute, Inc. | COM NEW | 621,894 | $3.05M | 1.4% | +621,894 | New | History |
| PMNProMIS Neurosciences Inc. | COM | 2,645,128 | $2.51M | 1.2% | −145,570−5.2% | Reduced | History |
| OPTNOptiNose, Inc. | COM NEW | 370,269 | $2.47M | 1.2% | −487,140−56.8% | ReducedConverted for a 1-for-15 split | History |
| URGNUroGen Pharma Ltd. | COM | 187,843 | $2.00M | 0.9% | −570,943−75.2% | Reduced | History |
Sold out since Q3 2024 (7)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,000,000 | $11.9M | 3.6% | History |
| ACLXArcellx, Inc. | COMMON STOCK | 100,000 | $8.35M | 2.5% | History |
| OTLKOutlook Therapeutics, Inc. | Stock | 1,293,028 | $6.90M | 2.1% | History |
| TCRXTScan Therapeutics, Inc. | COM | 1,016,375 | $5.06M | 1.5% | History |
| RNACCartesian Therapeutics, Inc. | COM NEW | 200,000 | $3.22M | 1.0% | History |
| VTGNVistagen Therapeutics, Inc. | COM | 674,075 | $2.03M | 0.6% | History |
| CLYMClimb Bio, Inc. | COM | 248,168 | $1.26M | 0.4% | History |